Indications and uses
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat
use only with enclosed dosing cup adults and children 6 years and over 2 teaspoonfuls (tsp) daily; do not take more than 2 teaspoonfuls (tsp) in 24 hours children 2 to under 6 years of age 1 teaspoonful (tsp) daily; do not take more than 1 teaspoonful (tsp) in 24 hours children under 2 years of age ask a doctor consumers with liver or kidney disease ask a doctor
safety sealed: do not use if imprinted safety seal is torn or missing store between 20° and 25°C (68° and 77°F)
Drug Facts
Loratadine 5 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
Do not use if you have ever had an allergic reaction to this product or any of its ingredients.
Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose.
When using this product do not take more than directed. Taking more than directed may cause drowsiness.
Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
| adults and children 6 years and over | 2 teaspoonfuls (tsp) daily; do not take more than 2 teaspoonfuls (tsp) in 24 hours |
| children 2 to under 6 years of age | 1 teaspoonful (tsp) daily; do not take more than 1 teaspoonful (tsp) in 24 hours |
| children under 2 years of age | ask a doctor |
| consumers with liver or kidney disease | ask a doctor |
glycerin, grape flavor, maltitol solution, masking agent, noncrystallizing sorbitol solution, phosphoric acid, polyethylene glycol, propylene glycol, purified water, sodium benzoate, sodium metabisulfite, sodium phosphate monobasic dihydrate, sucralose powder.
call 1-800-632-6900
DISTRIBUTED BY THE KROGER CO., CINCINNATI, OH 45202
Compare to the active ingredient in CHILDREN'S CLARITIN®
**See side panel.
NDC 30142-092-08
2 YEARS & Older
Non-drowsy*
Children's
ALLERGY RELIEF
Loratadine Oral Solution 5 mg/5 mL
Antihistamine
Dye-Free
24 Hour Relief of:
Sugar Free
Indoor & Outdoor Allergies
*When taken as directed.
See Drug Facts Panel.
Grape Flavor
4 FL OZ (120 mL)
Kroger®
FROM OUR FAMILY TO YOURS

| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 30142-092-08 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-6ac0-f424-e053-dadaa90a57ce | Children's Non-Drowsy Allergy Relief 24-hour |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 30142-092-08 | Childrens Non-Drowsy Allergy Relief 24-Hour | 120 mL in 1 BOTTLE | SOLUTION | 120 | 1 | |
| 30142-092-08 | Childrens Non-Drowsy Allergy Relief 24-Hour | 1 in 1 CARTON | SOLUTION | 1 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Loratadine | ACTIVE INGREDIENT | 7AJO3BO7QN | 1 | |
| Loratadine | ACTIVE MOIETY | 7AJO3BO7QN | 1 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| phosphoric acid | INACTIVE INGREDIENT | E4GA8884NN | 1 | |
| polyethylene glycols | INACTIVE INGREDIENT | 3WJQ0SDW1A | 1 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| sodium benzoate | INACTIVE INGREDIENT | OJ245FE5EU | 1 | |
| sodium metabisulfite | INACTIVE INGREDIENT | 4VON5FNS3C | 1 | |
| sodium phosphate, monobasic, dihydrate | INACTIVE INGREDIENT | 5QWK665956 | 1 | |
| sorbitol | INACTIVE INGREDIENT | 506T60A25R | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 30142-092 | 30142-092-08 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Loratadine | 7AJO3BO7QN | ACTIB |
| glycerin | PDC6A3C0OX | IACT |
| sorbitol | 506T60A25R | IACT |
| phosphoric acid | E4GA8884NN | IACT |
| polyethylene glycols | 3WJQ0SDW1A | IACT |
| propylene glycol | 6DC9Q167V3 | IACT |
| water | 059QF0KO0R | IACT |
| sodium benzoate | OJ245FE5EU | IACT |
| sodium metabisulfite | 4VON5FNS3C | IACT |
| sodium phosphate, monobasic, dihydrate | 5QWK665956 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | TABLET / ORAL | 30 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| sodium phosphate, monobasic, dihydrate | SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE | 5QWK665956 | SOLUTION / OPHTHALMIC | 2 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION, EXTENDED RELEASE / ORAL | 24 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION, CONCENTRATE / ORAL | 300 mg/1ml | ||
| sorbitol | SORBITOL | 506T60A25R | CAPSULE / ORAL | 1111 mg | ||
| sorbitol | SORBITOL | 506T60A25R | TABLET / ORAL | 337.28 mg | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / INFILTRATION | 0.05 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | ELIXIR / ORAL | 5.02 mg/5ml | ||
| sorbitol | SORBITOL | 506T60A25R | CREAM, AUGMENTED / TOPICAL | 15 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | TABLET, CHEWABLE / ORAL | 0.2 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAVENOUS | 4000 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRACARDIAC | 0.09 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | SOLUTION / ORAL | 660 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, SOLUBLE / BUCCAL | 5 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | INJECTION / INTRAVENOUS | 1294 mg | ||
| sorbitol | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| sorbitol | SORBITOL | 506T60A25R | INJECTION / INTRA-ARTICULAR | 45 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SYSTEM / IONTOPHORESIS | 0.5 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM, EXTENDED RELEASE / TRANSDERMAL | 58.13 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | SYSTEM / TOPICAL | 2 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | SPONGE / TOPICAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAMUSCULAR | 7459 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | CREAM / VAGINAL | 0.56 %w/w | ||
| sodium phosphate, monobasic, dihydrate | SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE | 5QWK665956 | INJECTION, SOLUTION / INTRATHECAL | 0.01 %w/v | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION / ORAL | 40 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| sorbitol | SORBITOL | 506T60A25R | CREAM / TOPICAL | 36.8 %w/w | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAMUSCULAR | 4000 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 63.4 %w/v | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | SOLUTION / RESPIRATORY (INHALATION) | 0.3 %w/w | ||
| sodium benzoate | SODIUM BENZOATE | OJ245FE5EU | TABLET, FILM COATED / ORAL | 1 mg | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION, AUGMENTED / TOPICAL | 2070 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | OINTMENT / TOPICAL | ADJ PH | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| sorbitol | SORBITOL | 506T60A25R | SYRUP / ORAL | 4370 mg/5ml | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| sodium metabisulfite | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRABURSAL | 0.2 %w/v | ||
| propylene glycol | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A076805-001 | LORATADINE | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A076805-001 | LORATADINE | 1MG/ML | SYRUP / ORAL | 2004-08-20 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 83c49382-642f-494f-b784-e4513b2c3bbf | 86730925-e349-4e1e-9140-c73c1facda45 | 2013-08-01 | Warnings | 83c49382-642f-494f-b784-e4513b2c3bbf 86730925-e349-4e1e-9140-c73c1facda45 |
Adverse event summaries are temporarily unavailable. Other product information remains available.